Tharimmune Stock Analysis

THAR Stock   3.13  0.59  15.86%   
Tharimmune is undervalued with Real Value of 3.5 and Target Price of 4.0. The main objective of Tharimmune stock analysis is to determine its intrinsic value, which is an estimate of what Tharimmune is worth, separate from its market price. There are two main types of Tharimmune's stock analysis: fundamental analysis and technical analysis.
The Tharimmune stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tharimmune is usually not traded on Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday. Tharimmune Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tharimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
To learn how to invest in Tharimmune Stock, please use our How to Invest in Tharimmune guide.

Tharimmune Stock Analysis Notes

The company has price-to-book ratio of 0.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tharimmune recorded a loss per share of 22.35. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 28th of May 2024. To find out more about Tharimmune contact the company at 908 955 3140 or learn more at https://www.tharimmune.com.

Tharimmune Investment Alerts

Tharimmune generated a negative expected return over the last 90 days
Tharimmune has high historical volatility and very poor performance
Tharimmune has a very high chance of going through financial distress in the upcoming years
Tharimmune was previously known as Hillstream Biopharma and was traded on NASDAQ Exchange under the symbol HILS.
Net Loss for the year was (9.32 M) with profit before overhead, payroll, taxes, and interest of 0.
Tharimmune generates negative cash flow from operations
Tharimmune has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Upcoming and Recent Events

21st of March 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Tharimmune Largest EPS Surprises

Earnings surprises can significantly impact Tharimmune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-07
2023-09-30-0.06-0.11-0.0583 
2024-02-23
2023-12-31-1.25-0.710.5443 
2023-08-30
2023-06-30-0.16-4.0-3.842400 
View All Earnings Estimates

Tharimmune Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.79 M.

Tharimmune Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.85)(0.89)
Return On Capital Employed(1.04)(0.98)
Return On Assets(0.85)(0.89)
Return On Equity(1.02)(0.97)

Management Efficiency

Tharimmune has return on total asset (ROA) of (0.8347) % which means that it has lost $0.8347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.734) %, meaning that it created substantial loss on money invested by shareholders. Tharimmune's management efficiency ratios could be used to measure how well Tharimmune manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/24/2024, Return On Tangible Assets is likely to drop to -0.89. In addition to that, Return On Capital Employed is likely to grow to -0.98. At this time, Tharimmune's Total Assets are relatively stable compared to the past year. As of 07/24/2024, Net Tangible Assets is likely to grow to about 6.7 M, while Other Current Assets are likely to drop slightly above 10.5 K.
Last ReportedProjected for Next Year
Book Value Per Share 6.99  7.34 
Tangible Book Value Per Share 6.99  7.34 
Enterprise Value Over EBITDA 0.10  0.11 
Price Book Value Ratio 1.09  1.15 
Enterprise Value Multiple 0.10  0.11 
Price Fair Value 1.09  1.15 
Enterprise Value-961.8 K-913.7 K
The analysis of Tharimmune's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Tharimmune's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Tharimmune Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.589
Return On Assets
(0.83)
Return On Equity
(1.73)

Technical Drivers

As of the 24th of July, Tharimmune has the Variance of 48.19, coefficient of variation of (1,108), and Risk Adjusted Performance of (0.05). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tharimmune, as well as the relationship between them. Please validate Tharimmune mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Tharimmune is priced more or less accurately, providing market reflects its prevalent price of 3.13 per share. Given that Tharimmune has information ratio of (0.10), we advise you to double-check Tharimmune's current market performance to make sure the company can sustain itself at a future point.

Tharimmune Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tharimmune middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tharimmune. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Tharimmune Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tharimmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tharimmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tharimmune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Tharimmune Predictive Daily Indicators

Tharimmune intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tharimmune stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Tharimmune Corporate Filings

23rd of July 2024
Other Reports
ViewVerify
15th of July 2024
Other Reports
ViewVerify
28th of June 2024
Other Reports
ViewVerify
8K
20th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
12th of June 2024
Other Reports
ViewVerify
8K
11th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
7th of June 2024
Other Reports
ViewVerify
8K
22nd of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Tharimmune Forecast Models

Tharimmune's time-series forecasting models are one of many Tharimmune's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tharimmune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Tharimmune Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tharimmune prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tharimmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tharimmune. By using and applying Tharimmune Stock analysis, traders can create a robust methodology for identifying Tharimmune entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Tharimmune Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tharimmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tharimmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.0Strong Buy1Odds
Tharimmune current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Tharimmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tharimmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tharimmune, talking to its executives and customers, or listening to Tharimmune conference calls.
Tharimmune Analyst Advice Details

Tharimmune Stock Analysis Indicators

Tharimmune stock analysis indicators help investors evaluate how Tharimmune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tharimmune shares will generate the highest return on investment. By understating and applying Tharimmune stock analysis, traders can identify Tharimmune position entry and exit signals to maximize returns.
Begin Period Cash Flow6.5 M
Common Stock Shares Outstanding1.3 M
Total Stockholder Equity9.1 M
Cash And Short Term Investments10.9 M
Cash10.9 M
Accounts Payable908.6 K
Net Debt-10.9 M
50 Day M A5.5754
Total Current Liabilities1.8 M
Other Operating Expenses9.5 M
Stock Based Compensation831.9 K

Additional Tools for Tharimmune Stock Analysis

When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.